Cerebral microbleeds is associated with dementia in Parkinson’s disease

Wan, Huijuan; Chen, Huimin; Zhang, Meimei; Fang, Tao; Wang, Yilong

doi:10.1007/s13760-022-01918-z

Cited by 3 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The extent and severity of cerebral small vessel disease (CSVD) has considerable impact on the severity of CI. A meta-analysis of its influence on cognitive function in PD showed different effects—most on EF, memory and overall cognitive function [ 441 ], whereas others found no correlation between CSVD pathology and dementia [ 442 , 443 ]. Lacunes were independently associated with worse attention and processing speed and may accelerate the course of PD [ 444 ].…”

Section: Impact Of Other Co-pathologies In Cognition In Pdmentioning

confidence: 99%

“…Increased perivascular space in the basal ganglia and WMH was associated with cognitive decline in PD [ 203 , 445 ], as were cerebral microbleeds (CMB), which were both related to hypertension [ 397 ]. CMBs were significantly associated with PDD [ 396 , 443 ], while others associated PDD with amyloid-related CMBs and reduced hippocampal volume [ 446 ]. The association of severe CAA with PDD has been reported repeatedly [ 34 , 398 , 405 ], whereas, according to others, cerebrovascular disease and TDP-43 pathologies had no definite impact on the development of PDD [ 395 ].…”

Section: Impact Of Other Co-pathologies In Cognition In Pdmentioning

confidence: 99%

See 1 more Smart Citation

Pathobiology of Cognitive Impairment in Parkinson Disease: Challenges and Outlooks

Jellinger

2023

IJMS

View full text Add to dashboard Cite

Cognitive impairment (CI) is a characteristic non-motor feature of Parkinson disease (PD) that poses a severe burden on the patients and caregivers, yet relatively little is known about its pathobiology. Cognitive deficits are evident throughout the course of PD, with around 25% of subtle cognitive decline and mild CI (MCI) at the time of diagnosis and up to 83% of patients developing dementia after 20 years. The heterogeneity of cognitive phenotypes suggests that a common neuropathological process, characterized by progressive degeneration of the dopaminergic striatonigral system and of many other neuronal systems, results not only in structural deficits but also extensive changes of functional neuronal network activities and neurotransmitter dysfunctions. Modern neuroimaging studies revealed multilocular cortical and subcortical atrophies and alterations in intrinsic neuronal connectivities. The decreased functional connectivity (FC) of the default mode network (DMN) in the bilateral prefrontal cortex is affected already before the development of clinical CI and in the absence of structural changes. Longitudinal cognitive decline is associated with frontostriatal and limbic affections, white matter microlesions and changes between multiple functional neuronal networks, including thalamo-insular, frontoparietal and attention networks, the cholinergic forebrain and the noradrenergic system. Superimposed Alzheimer-related (and other concomitant) pathologies due to interactions between α-synuclein, tau-protein and β-amyloid contribute to dementia pathogenesis in both PD and dementia with Lewy bodies (DLB). To further elucidate the interaction of the pathomechanisms responsible for CI in PD, well-designed longitudinal clinico-pathological studies are warranted that are supported by fluid and sophisticated imaging biomarkers as a basis for better early diagnosis and future disease-modifying therapies.

show abstract

Section: Impact Of Other Co-pathologies In Cognition In Pdmentioning

confidence: 99%

Section: Impact Of Other Co-pathologies In Cognition In Pdmentioning

confidence: 99%

Pathobiology of Cognitive Impairment in Parkinson Disease: Challenges and Outlooks

Jellinger

2023

IJMS

View full text Add to dashboard Cite

show abstract

Is white matter hyperintensity burden associated with cognitive and motor impairment in patients with parkinson’s disease? A systematic review and meta-analysis

Carvalho de Abreu,

Pieruccini-Faria,

Son

et al. 2024

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions

Zarkali,

Thomas,

Zetterberg

et al. 2024

Nat Commun

View full text Add to dashboard Cite

A major challenge in Parkinson’s disease is the variability in symptoms and rates of progression, underpinned by heterogeneity of pathological processes. Biomarkers are urgently needed for accurate diagnosis, patient stratification, monitoring disease progression and precise treatment. These were previously lacking, but recently, novel imaging and fluid biomarkers have been developed. Here, we consider new imaging approaches showing sensitivity to brain tissue composition, and examine novel fluid biomarkers showing specificity for pathological processes, including seed amplification assays and extracellular vesicles. We reflect on these biomarkers in the context of new biological staging systems, and on emerging techniques currently in development.

show abstract

Cerebral microbleeds is associated with dementia in Parkinson’s disease

Cited by 3 publications

References 26 publications

Pathobiology of Cognitive Impairment in Parkinson Disease: Challenges and Outlooks

Pathobiology of Cognitive Impairment in Parkinson Disease: Challenges and Outlooks

Is white matter hyperintensity burden associated with cognitive and motor impairment in patients with parkinson’s disease? A systematic review and meta-analysis

Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions

Contact Info

Product

Resources

About